BridgeBio Oncology Therapeutics

IPO

BridgeBio Oncology Therapeutics (BBOT) | Best-in-RAS

Public · South San Francisco, United States · Founded 2024 · $200.0M raised

Employees
51–200
Founded
2024
Business Model
B2B
Website
bbotx.com
Total Funding
$200.0M
Last Round
$200.0M Series BMay 2024
Rounds
1
Type
Public

About

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio Pharma, BBOT completed a $200M private financing in May 2024 with leading oncology investors. The company is advancing three programs — BBO-8520, BBO-10203, and BBO-11818 — targeting KRAS and PI3Kα pathway cancers.

Summary

BridgeBio Oncology Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2024. It has raised $200.0M in total across 1 round, most recently a $200.0M Series B round in May 2024. Investors include Cormorant Asset Management, Omega Funds and Deerfield Management.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SPAC MergerSPAC MergerAug 2025

Sign up to see all 2 rounds

Series B through SPAC Merger — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

BridgeBio Oncology Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/bridgebio-oncology-therapeutics"><img src="https://indexed.vc/api/badge/company/bridgebio-oncology-therapeutics" alt="BridgeBio Oncology Therapeutics on Indexed.vc" width="260" height="76" /></a>